Health

  • June 23, 2026

    Feds Tout AI's Role In $6.5B Healthcare Fraud Crackdown

    Federal authorities said Tuesday that artificial intelligence and sophisticated data analysis helped them detect and prosecute healthcare fraud as part of a national crackdown that resulted in charges against 455 defendants.

  • June 23, 2026

    Insurer Says Late Notice Bars Wrongful Death Suit Coverage

    An insurer for a New Jersey facility for people with disabilities told a federal court Monday that it does not owe coverage in an underlying wrongful death suit because the group home did not inform the insurer of the claim until two years after the suit was filed.

  • June 23, 2026

    Gene Therapy Developer Sangamo Hits Ch. 11 With Sale Plans

    Sangamo Therapeutics Inc. filed for bankruptcy protection in Delaware on Tuesday with offers to sell parts of its genetic therapy development programs to Eli Lilly and Co. and Astellas Pharma Inc.

  • June 22, 2026

    7th Circ. Won't Unblock Fla. Gender Care Suit Amid Appeal

    A split Seventh Circuit on Monday refused to pause an Illinois federal judge's preliminary injunction blocking the lawsuit from Florida's attorney general targeting medical groups' policies on youth gender-affirming care while the Sunshine State official appeals.

  • June 22, 2026

    Cassava Investors Ink $31M Drug Suit Deal Alongside Appeal

    Cassava Sciences investors have asked a Texas federal judge to preliminarily approve a $31 million settlement that ends their claims the pharmaceutical company inflated its stock prices with misleading information about its Alzheimer's drug research, a deal that could be upended if the court's class certification order is reversed on appeal.

  • June 22, 2026

    FTC Requires Fix For Aurobindo's $250M Lannett Deal

    The Federal Trade Commission is allowing Aurobindo Pharma Ltd. to move ahead with its planned $250 million acquisition of Lannett Co. Inc., after the pharmaceutical company agreed to unload four generic drug products to prevent potential overlaps.

  • June 22, 2026

    No Trial For Splenda Maker, Scientist In Defamation Suit

    Splenda maker TC Heartland LLC and the scientist whom it accused of defamation were sent packing from North Carolina federal court Monday, after a judge found neither had offered evidence to overcome the other's First Amendment right to talk about scientific research.

  • June 22, 2026

    BakerHostetler Corporate Team Gains Chicago Healthcare Pro

    BakerHostetler announced Monday that it has added a healthcare-focused transactional partner to its business practice group to bolster its Chicago roster.

  • June 22, 2026

    Sodexo Can't Wipe Out Worker's Nicotine Fee Suit

    A California federal judge refused to toss a Sodexo worker's proposed class action alleging the global food services company wrongly charged nicotine-using employees $1,200 more a year for health insurance, opening discovery on allegations that a wellness program implementing the surcharge didn't meet all federal requirements.

  • June 22, 2026

    Justices To Hear Fight Over Reach Of Bivens Prison Suits

    The U.S. Supreme Court agreed Monday to hear a case over whether a federal inmate can use a 1971 high court precedent to pursue damages from prison officials for allegedly failing to provide adequate medical care after a 2021 prison fight.

  • June 22, 2026

    NORML Fights Exclusion From DEA Pot Rescheduling Hearing

    The National Organization for the Reform of Marijuana Laws, a leading cannabis consumer advocate, has asked the U.S. Drug Enforcement Administration to reconsider its move freezing out all pro-reform voices from upcoming hearings on a proposal to reschedule marijuana.

  • June 22, 2026

    Yale Health Escapes Trade Law Claim In Insemination Suit

    Yale New Haven Health Services Corp. has defeated Connecticut trade law, emotional distress and informed consent claims in a lawsuit accusing a doctor of fraudulently using his own sperm to inseminate a fertility patient, but the hospital network holding entity must face a fraud allegation, a state judge has ruled.

  • June 22, 2026

    NJ Medical Center Sued Over Alleged Patient Data Tracking

    A New Jersey medical center deployed third-party tracking tools on its website to collect sensitive information about users' searches for doctors and medical conditions, appointment requests and patient portal activity without users' knowledge or consent, two patients claimed in a proposed federal class action.

  • June 22, 2026

    Holland & Knight Adds Jones Day Atty To Atlanta, DC Teams

    Holland & Knight LLP has bolstered its ranks in Atlanta and Washington, D.C., by adding an attorney from Jones Day with experience helping clients navigate investigations brought by enforcers including the U.S. Department of Justice and the U.S. Securities and Exchange Commission. 

  • June 22, 2026

    Wellstar Reaches Deal In Patient Data-Sharing Suit

    Georgia's largest healthcare system has reached a settlement with a group of anonymous patients who alleged that the confidential health information of "millions" was shared with Meta Platform Inc. without consent using tracking and collection tools, according to a joint notice Monday.

  • June 22, 2026

    USTR Launches Probe Into German Pharma Costs

    The U.S. Trade Representative has opened an investigation into whether Germany has been underpaying for certain pharmaceutical products in a way that burdens U.S. consumers with added costs, which could lead to added tariffs.

  • June 22, 2026

    Gov't Says It Should Face Vax IP Claims, Not Moderna

    The U.S. Department of Justice has told the Federal Circuit that multibillion-dollar patent infringement litigation should be directed at the government, instead of Moderna, for the drugmaker's development and supply of COVID vaccines during the pandemic.

  • June 22, 2026

    Paul Weiss, Kirkland Steer $10.9B AbbVie, Apogee Deal

    AbbVie said Monday it has agreed to buy Apogee Therapeutics, a company developing therapies for inflammatory and immunological diseases, at a total equity value of approximately $10.9 billion, with Paul Weiss Rifkind Wharton & Garrison LLP and Kirkland & Ellis LLP advising. 

  • June 18, 2026

    Eli Lilly Weight Drug TM Deal Too Secretive, Ind. Judge Says

    An Indiana federal judge on Thursday refused to sign off on a confidential settlement that would bar a telehealth company from selling knock-offs of Eli Lilly's weight-loss medications, saying the companies didn't provide enough information for him to consider the deal.

  • June 18, 2026

    Express Scripts Can't Ditch Meta Wiretap Suit Yet

    A California federal judge refused to dismiss a proposed class action alleging Express Scripts lets Meta secretly read consumers' communications, saying a consumer sufficiently claimed the online pharmacy allowed Meta's unauthorized collection of personal health information.

  • June 18, 2026

    Fertility Chain Beats Suit Alleging Bogus Embryo Test Claims

    A fertility clinic chain has defeated a proposed class action accusing it of deceptively marketing its preimplantation genetic testing, after a Colorado federal judge found none of the patients claimed their own tests were inaccurate or caused a miscarriage or failed pregnancy.

  • June 18, 2026

    Novo Nordisk Sued Over Data Hack Tied To Extortionist Group

    Novo Nordisk was hit with a proposed negligence class action in New Jersey federal court alleging the pharmaceutical giant failed to have adequate data security measures in place to protect sensitive personal health information of patients and employees from being exposed to a cybercriminal extortionist group.

  • June 18, 2026

    Mangione Withdraws Psych Defense Notice In NY Murder Trial

    Luigi Mangione's counsel told a New York state justice that they're withdrawing their notice indicating they would invoke a psychiatric defense in the death of UnitedHealthcare CEO Brian Thompson.

  • June 18, 2026

    Tort Report: Meta Set To Face Facebook Sex Trafficking Trial

    An upcoming trial in Texas for a first-of-its-kind case against Meta and claims against a health clinic owned by a U.S. senator lead Law360's Tort Report, which compiles recent personal injury and medical malpractice news that may have flown under the radar.

  • June 18, 2026

    Calif., Carbon Health $4.5M Deal Over Clinic Biz Nears Review

    A $4.5 million settlement resolving California's allegations that recently bankrupt urgent care company Carbon Health Technologies Inc. violated the state's prohibition on the corporate practice of medicine and misled patients about its billing practices is nearing court review, according to individuals familiar with the matter.

Expert Analysis

  • Becoming The Biz-Savvy GC That Portfolio Companies Need

    Author Photo

    Candidates for general counsel roles at private equity-backed portfolio companies should prioritize proving their sector-specific experience, commercial judgment and ease with uncertainty — and attorneys hoping to be candidates in five to 10 years should start working on those skills now, says Dimitri Mastrocola at Major Lindsey.

  • AI Regulatory Gaps May Fuel FCA Enforcement Action

    Author Photo

    The intersection of artificial intelligence and False Claims Act enforcement presents legal risk for government contractors across several industries, particularly in the absence of a federal regulatory framework explicitly governing its development and use, say attorneys at O’Melveny.

  • Series

    Judges On AI: How Courts Can Survive The Tech Revolution

    Author Photo

    Colorado Supreme Court Justice Maria Berkenkotter and Colorado Court of Appeals Judge Lino Lipinsky de Orlov discuss how artificial intelligence has already fundamentally altered the legal system and offer tips for courts navigating deepfakes, hallucinations and a gap in access to AI tools.

  • 'Skinny Label' Arguments Spotlight Induced Infringement Risk

    Author Photo

    Recent oral arguments before the U.S. Supreme Court in Hikma Pharmaceuticals v. Amarin Pharma highlight the uncertain boundary between lawful generic competition through so-called skinny labels and induced patent infringement, with potential implications for patent holders’ communication, enforcement and causation strategies across industries, says Anton Hopen at Trenam.

  • 3 AI Adoption Mistakes GCs Should Avoid

    Author Photo

    The pressure in-house legal teams face to quickly adopt artificial intelligence tools, combined with budget constraints and the need to evaluate a crowded market of options, sets the stage for implementation mistakes that are often difficult to undo, says former 23andMe general counsel Guy Chayoun.

  • Series

    Playing Basketball Makes Me A Better Lawyer

    Author Photo

    My grandfather used to say "I wear your jersey" as shorthand for wholly committing to support someone with loyalty and integrity — ideals that have shaped my life on the basketball court and in legal practice, says Tracy Schimelfenig at Schimelfenig Legal.

  • EPA Listing Signals New Scrutiny Of Drugs In Drinking Water

    Author Photo

    The recent publication of the U.S. Environmental Protection Agency's latest draft drinking water contaminant list highlights pharmaceuticals as a category of concern, marking the start of a process that could shape future research priorities, monitoring requirements, and federal and state actions, say attorneys at Morgan Lewis.

  • Opinion

    5th Circ.'s Abortion Pill Order Is Shaky On Multiple Grounds

    Author Photo

    The Fifth Circuit's recent order in Louisiana v. U.S. Food and Drug Administration, reinstating an in-person dispensing requirement for the abortion medication mifepristone, seems to turn federalism upside-down, and is also questionable for several other reasons, says Gregory Curtner at Curtner Law.

  • Series

    The Biz Court Digest: Georgia Court Has Business On Its Mind

    Author Photo

    Thanks to recent legislation, the Georgia State-wide Business Court will soon offer business litigants greater access to the court than ever before, further enhancing the court's emphasis on efficiency, predictability and accessibility for sophisticated commercial disputes, says former GSBC judge Walt Davis at Jones Day.

  • 5 Takeaways From Justices' Subpoena Fight Ruling

    Author Photo

    The U.S. Supreme Court's recent decision in First Choice v. Davenport fortifies a line of First Amendment associational privacy cases stretching back nearly 70 years, and ensures that organizations subject to government demands for donor information have a meaningful federal forum in which to defend their constitutional rights, say attorneys at DLA Piper.

  • Mass. Draft Regs Signal Nationwide Scrutiny Of Junk Fees

    Author Photo

    Massachusetts Attorney General Andrea Campbell's new draft regulations for assisted living facilities is only her latest move in the war on junk fees — and part of a national reordering of consumer protection enforcement in which states are aggressively and creatively asserting authority, says Steve Provazza at Arnall Golden.

  • 4 Emerging Approaches To AI Protective Order Language

    Author Photo

    Over the last year, at least five federal district courts have issued or analyzed specific protective order provisions restricting the use of generative artificial intelligence platforms with protected materials, establishing that proactive AI-specific provisions are now standard practice and demonstrating that no single model works for every case, says Joel Bush at Kilpatrick.

  • What Justices Are Focusing On In 'Skinny Label' Patent Case

    Author Photo

    Though Hikma v. Amarin appears to be a patent dispute that could reshape inducement doctrine in the pharmaceutical context, oral argument suggests the U.S. Supreme Court may treat this as primarily a pleading-stage dispute, with important unresolved questions lurking beneath the surface, says Shashank Upadhye at Upadhye Tang.

  • Accelerated Psychedelic Therapy Pathways Require Caution

    Author Photo

    President Donald Trump's new executive order aiming to accelerate the approval of psychedelic drugs for the treatment of mental health disorders will likely bolster investigational psychedelic therapies, but parties within the psychedelic product supply chain will still need to prepare for potentially burdensome compliance requirements, say attorneys at Morgan Lewis.

  • Heppner Ruling Left AI Privilege Risk For Lawyers Unresolved

    Author Photo

    While a New York federal judge’s recent ruling in U.S. v. Heppner resolved a privilege question surrounding client-side artificial intelligence use, it did not address how to mitigate the risks that can arise when confidential information enters the operative context of an AI system used by an attorney, says Jianfei Chen at Quarles & Brady​​​​​​​.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.